QQ客服 官方微博 反馈留言

	Elevated high sensitivity troponin T (HSTNT) during front-line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone +/-rituximab (CHOP+/-R) or cyclophosphamide, epirubicin, vincristine and prednisone +/-rituximab (CEPOP+/-R) correlates with a decline in left ventricular ejection fraction (LVEF) in patients with aggressive B-cell lymphoma: Results from a randomized prospective Clinical Trial NCT00854568
	Xue K., Gu J.J., Zhang Q., Liu X., Wang J., Luo J., Hernandez-Ilizaliturri F.J., Fernandez S.F., Czuczman M.S., Cao J., Hong X., Guo Y.
刊名	Blood
	2014
卷号	124
ISSN号	0006-4971
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4881833
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Xue K., Gu J.J., Zhang Q., Liu X., Wang J., Luo J., Hernandez-Ilizaliturri F.J., Fernandez S.F., Czuczman M.S., Cao J., Hong X., Guo Y.. Elevated high sensitivity troponin T (HSTNT) during front-line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone +/-rituximab (CHOP+/-R) or cyclophosphamide, epirubicin, vincristine and prednisone +/-rituximab (CEPOP+/-R) correlates with a decline in left ventricular ejection fraction (LVEF) in patients with aggressive B-cell lymphoma: Results from a randomized prospective Clinical Trial NCT00854568[J]. Blood,2014,124.
APA	Xue K., Gu J.J., Zhang Q., Liu X., Wang J., Luo J., Hernandez-Ilizaliturri F.J., Fernandez S.F., Czuczman M.S., Cao J., Hong X., Guo Y..(2014).Elevated high sensitivity troponin T (HSTNT) during front-line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone +/-rituximab (CHOP+/-R) or cyclophosphamide, epirubicin, vincristine and prednisone +/-rituximab (CEPOP+/-R) correlates with a decline in left ventricular ejection fraction (LVEF) in patients with aggressive B-cell lymphoma: Results from a randomized prospective Clinical Trial NCT00854568.Blood,124.
MLA	Xue K., Gu J.J., Zhang Q., Liu X., Wang J., Luo J., Hernandez-Ilizaliturri F.J., Fernandez S.F., Czuczman M.S., Cao J., Hong X., Guo Y.."Elevated high sensitivity troponin T (HSTNT) during front-line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone +/-rituximab (CHOP+/-R) or cyclophosphamide, epirubicin, vincristine and prednisone +/-rituximab (CEPOP+/-R) correlates with a decline in left ventricular ejection fraction (LVEF) in patients with aggressive B-cell lymphoma: Results from a randomized prospective Clinical Trial NCT00854568".Blood 124(2014).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。